Insmed, Inc. (INSM)
119.46
+0.92
(+0.78%)
USD |
NASDAQ |
Aug 31, 10:58
Insmed Free Cash Flow : -837.67M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -837.67M |
| March 31, 2026 | -951.64M |
| December 31, 2025 | -997.58M |
| September 30, 2025 | -906.14M |
| June 30, 2025 | -868.57M |
| March 31, 2025 | -789.25M |
| December 31, 2024 | -705.80M |
| September 30, 2024 | -634.81M |
| June 30, 2024 | -589.39M |
| March 31, 2024 | -587.33M |
| December 31, 2023 | -549.54M |
| September 30, 2023 | -525.62M |
| June 30, 2023 | -476.84M |
| March 31, 2023 | -454.37M |
| December 31, 2022 | -410.32M |
| September 30, 2022 | -387.75M |
| June 30, 2022 | -374.27M |
| March 31, 2022 | -347.99M |
| December 31, 2021 | -370.59M |
| September 30, 2021 | -353.04M |
| June 30, 2021 | -335.53M |
| March 31, 2021 | -294.44M |
| December 31, 2020 | -225.59M |
| September 30, 2020 | -215.30M |
| June 30, 2020 | -222.85M |
| Date | Value |
|---|---|
| March 31, 2020 | -275.66M |
| December 31, 2019 | -292.92M |
| September 30, 2019 | -308.04M |
| June 30, 2019 | -308.42M |
| March 31, 2019 | -275.54M |
| December 31, 2018 | -271.07M |
| September 30, 2018 | -248.42M |
| June 30, 2018 | -219.77M |
| March 31, 2018 | -198.69M |
| December 31, 2017 | -162.62M |
| September 30, 2017 | -171.43M |
| June 30, 2017 | -165.03M |
| March 31, 2017 | -158.12M |
| December 31, 2016 | -150.91M |
| September 30, 2016 | -120.13M |
| June 30, 2016 | -112.73M |
| March 31, 2016 | -108.12M |
| December 31, 2015 | -104.15M |
| September 30, 2015 | -90.67M |
| June 30, 2015 | -89.61M |
| March 31, 2015 | -82.93M |
| December 31, 2014 | -69.77M |
| September 30, 2014 | -69.47M |
| June 30, 2014 | -62.15M |
| March 31, 2014 | -49.10M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Biogen, Inc. | 2.49B |
| Gilead Sciences, Inc. | 12.94B |
| Agios Pharmaceuticals, Inc. | -365.25M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -88.83M |
| Cash from Investing (Quarterly) | 24.51M |
| Cash from Financing (Quarterly) | 27.18M |
| Free Cash Flow Per Share (Quarterly) | -0.4375 |
| Free Cash Flow to Equity (Quarterly) | -93.93M |
| Free Cash Flow to Firm (Quarterly) | -71.48M |
| Free Cash Flow Yield | -3.27% |